icon-    folder.gif   Conference Reports for NATAP  
 
  Conference on Retroviruses
and Opportunistic Infections (CROI)
February 13-16, 2017, Seattle WA
Back grey_arrow_rt.gif
 
 
 
Long Acting HIV ART - is this the future? Nanoformulations - Implants
 
 
  talk at CROI by Flexner: LONG-ACTING ANTIRETROVIRAL THERAPY: A SHOT IN THE DARK OR A PARADIGM SHIFT? [for HIV & HCV ?]
 
- they have formed LEAP - Long Acting Extended Release ART Resource Program with researchers/community and pharmaceutical industry me members including Flexner
http://longactinghiv.org/
 
Charles W Flexner
Johns Hopkins University, Baltimore, MD, USA
http://www.croiwebcasts.org/console/player/33659?mediaType=slideVideo&
 
Albuvertide is long acting T20 -Presented at Glasgow2016 : Efficacy and safety of long acting HIV fusion inhibitor albuvirtide in antiretroviral-experienced adults with HIV-1: interim 48 week results from the randomized, controlled, phase 3, non-inferiority TALENT study
http://www.natap.org/2016/GLASGOW/GLASGOW_38.htm
 
EFdA/MK8591 is new Merck NRTI - data suggest potential for up to 1 year /implant
- http://natap.org/2016/CROI/croi_14.htm
 
-CROI: MK-8591 Concentrations at Sites of HIV Transmission and Replication
http://www.natap.org/2016/HIV/080516_03.htm
 
CROI:
LONG-ACTING IBALIZUMAB IN PATIENTS WITH MULTI-DRUG RESISTANT HIV-1: A 24-WEEK STUDY

 

New Gilead Capsid Inhibitor for HIV - (02/16/17)
 
CROI:
Discovery of Novel Potent HIV Capsid Inhibitors with Long-Acting Potential
 
- Injectable Cabotegravir+Rilpivirine -
 
CROI:Long-term Safety and Efficacy of CAB and RPV as 2-Drug Oral Maintenance Therapy
 
CROI:
A LONG-ACTING NANOFORMULATED CABOTEGRAVIR PRODRUG FOR IMPROVED ANTIRETROVIRAL THERAPY
- (02/23/17)
 
TAF IMPLANT - CROI:
In Vitro -In Vivo Evaluation of a Biodegradable Implant Containing TAF for HIV PrEP

 

devel